Fondaparinux in the management of patients with ST-elevation acute myocardial infarction
Alexander GG TurpieHamilton Health Sciences Corporation – General Division, Hamilton, ON, CanadaAbstract: The death rate of patients with ST-segment elevation myocardial infarction (STEMI) remains substantial. Fondaparinux is a synthetic selective Factor Xa inhibitor with a high efficacy a...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2006-12-01
|
| Series: | Vascular Health and Risk Management |
| Online Access: | https://www.dovepress.com/fondaparinux-in-the-management-of-patients-with-st-elevation-acute-myo-peer-reviewed-article-VHRM |